School of Medicine

Showing 1-10 of 21 Results

  • Nicholas Antonios Kalogriopoulos

    Nicholas Antonios Kalogriopoulos

    Postdoctoral Scholar, Genetics

    BioNick's broad research interests are in developing tools and technologies for research and therapeutic applications. Nick obtained a B.S. in Genetics and Molecular Biology from the University of Wisconsin-Madison. During his undergraduate career, he trained with Dr. Paul Sondel, where he worked on preclinical testing of novel immunotherapeutic agents for the treatment of neuroblastoma. He obtained a Ph.D. in Biomedical Science with Dr. Pradipta Ghosh, elucidating the structural basis of non-canonical G protein activation by a novel protein family of Guanine Nucleotide Exchange Modulators (GEMs). As a Postdoctoral Researcher with Professor Alice Ting at Stanford University, his current research focuses on developing a new system for programmable and user-controlled cellular behaviors for immuno-oncology applications.

  • Peter William Earl Kane

    Peter William Earl Kane

    Director, Research to the People, Genetics

    BioPeter is the Director of Research to the People @ Stanford (

    Rare Disease: Currently organizing a collaborative study for Hypophosphatasia, a rare metabolic bone disease. Please contact us if you would like to be involved!

    Oncology: Research to the People at Stanford is a program for patients who have exhausted their clinical options and need to move beyond standard of care. We generate deep sequencing and multi-omics data, create cell-lines, and host tumor boards to interrogate new therapeutic possibilities.

    Our vision is to produce 100 of the deepest cancer case studies possible.

    Research to the People joined Dr. Michael Snyder's Lab at Stanford Medicine in July 2021.

  • Saswati Karmakar

    Saswati Karmakar

    Postdoctoral Scholar, Genetics

    BioSaswati Karmakar obtained her undergraduate degree in Biotechnology at Guru Gobind Singh Indraprastha University, New Delhi. She pursued her Ph.D. in Biochemistry and Molecular Biology at the University of Nebraska Medical Center, Omaha, working on the molecular characterization of pancreatic cancer stem cells and their contribution to cancer initiation and progression. Then, she moved to Stanford University with the National Cancer Institute's F99/K00 award for a postdoctoral position in Monte Winslow's lab. Saswati's current research uses novel approaches such as molecular barcoding and high throughput sequencing to understand pancreatic cancer pathogenesis. Saswati's long-term research interest is to elucidate mechanisms of metastasis and ultimately find better therapeutic avenues for pancreatic cancer patients.

  • Maya M. Kasowski

    Maya M. Kasowski

    Assistant Professor of Medicine (Sean N Parker Center for Allergy and Asthma Research) of Pathology and, by courtesy, of Genetics

    BioI am a clinical pathologist and assistant professor in the Departments of Medicine, Pathology, and Genetics (by courtesy) at Stanford. I completed my MD-PhD training at Yale University and my residency training and a post-doctoral fellowship in the Department of Genetics at Stanford University. My experiences as a clinical pathologist and genome scientist have made me passionate about applying cutting-edge technologies to primary patient specimens in order to characterize disease pathologies at the molecular level. The core focus of my lab is to study the mechanisms by which genetic variants influence the risk of disease through effects on intermediate molecular phenotypes.

  • Mark A. Kay, M.D., Ph.D.

    Mark A. Kay, M.D., Ph.D.

    Dennis Farrey Family Professor of Pediatrics, and Professor of Genetics

    Current Research and Scholarly InterestsMark A. Kay, M.D., Ph.D. Director of the Program in Human Gene Therapy and Professor in the Departments of Pediatrics and Genetics. Respected worldwide for his work in gene therapy for hemophilia, Dr. Kay and his laboratory focus on establishing the scientific principles and developing the technologies needed for achieving persistent and therapeutic levels of gene expression in vivo. The major disease models are hemophilia, hepatitis C, and hepatitis B viral infections.